Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over ... (ion for the year ended December 31 2011 ...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year

Date:2/21/2012

ion for the year ended December 31, 2011, compared to $781 million for the prior year. The increase in adjusted cash provided by operating activities was the result of an increase in profitability and focus on working capital in 2011. On a GAAP basis, cash provided by operating activities was $720 million for the year ended December 31, 2011, compared to $931 million for the prior year. Capital expenditures were approximately $280 million in the current year as compared to approximately $193 million in the prior year. The increase is the result of our previously announced planned expansions and integration plans.

Mylan's leverage ratio, defined as total notional debt to adjusted EBITDA, was approximately 2.9:1 at December 31, 2011 as compared to 3.7:1 at December 31, 2010.

Non-GAAP Financial Measures Mylan is disclosing non-GAAP financial measures when providing financial results. Primarily due to acquisitions, Mylan believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with accounting principles generally accepted in the U.S. (GAAP). In addition to disclosing its financial results determined in accordance with GAAP, Mylan is disclosing non-GAAP results that exclude items such as amortization expense and other costs directly associated with the acquisitions as well as certain other expense, revenue and operating cash flow items in order to supplement investors' and other readers' understanding and assessment of the company's financial performance, because the company's management uses these measures internally for forecasting, budgeting and measuring its operating performance. In addition, the company believes that including EBITDA and supplemental adjustments applied in presenting adjusted EBITDA and our leverage ratio pursuant to our cre
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine technology :

1. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
2. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
3. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
4. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
5. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
6. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
7. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
8. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
9. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
10. Mylan Launches First Generic Version of Teveten® Tablets
11. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets

Post Your Comments:

(Date:5/19/2013)... , May 19, 2013 The non-surgical ... low temperature radiofrequency (RF) energy is effective in ... or reduces the need for medication 10 years ... presented today at the Digestive Disease Week (DDW) ... Florida . "The sustained ...

(Date:5/18/2013)... The Open Paradigm Project, in collaboration ... Psychiatry , and leading organizations in the movement ... media campaign showcasing video testimonials by individuals negatively ... on pathology and illness rather than wellness and ... Association,s (APA) rollout of its latest revision of ...

(Date:5/17/2013)... , May 17, 2013 The power of ... important ways in which mankind depends on the plant ... Garden,s multifaceted exhibition Wild Medicine: Healing ... on view from May 18 through September 8, ... The featured exhibition,s many attractions include a re-creation ...

Breaking Medicine Technology:Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2 Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3 New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2 New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3 Wild Medicine On View at The New York Botanical Garden Through Sept. 8 2

[0] Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy [0] New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses [0] Wild Medicine On View at The New York Botanical Garden Through Sept. 8

... FOLD ) today announced that John F. Crowley ... Chairman in order to devote more time to interests related ... role as Executive Chairman, Mr. Crowley will continue to perform ... will advise the current Amicus management team on corporate strategy ...

... The board of directors of Eli Lilly and Company (NYSE: ... second quarter of 2011 of $0.49 a share on outstanding ... 10, 2011 to shareholders of record at the close of ... innovation-driven corporation, is developing a growing portfolio of pharmaceutical products ...

Cached Medicine Technology:Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman 2

Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman Lilly Declares Second-Quarter 2011 Dividend

(Date:5/20/2013)... (PRWEB) May 20, 2013 The ... Confectionery, Snacks, Breakfast Cereals, Baking Mixes & Flour, ... Conventional) & Geography — Global Trends & Forecasts ... product market with analysis and forecasting of the ... also identifies the driving and restraining factors for ...

(Date:5/20/2013)... 2013 B. E. Smith, the ... healthcare providers, has been retained to lead a ... Oswego Hospital in Oswego, N.Y. The top executive ... Smith has recently placed more than 900 healthcare ... a 164-bed, Joint Commission-accredited, acute care facility offering ...

(Date:5/20/2013)... Irritable Bowel Syndrome, or IBS, is commonly characterized ... habits, and is a difficult condition in which the ... of the colon may overreact to food, stress, exercise ... to an infection or a stressful life event. The ... a protein composite found in foods processed from wheat ...

(Date:5/20/2013)... 2013 The main objective for the present ... into a single comprehensive report. The objective was to ... this industry. Thus, it is timely to examine the ... an urgent need in the life science industry for technologies ... in a high-throughput, multiplex and low-cost way. Proteomic technologies ...

(Date:5/20/2013)... May 20, 2013 Pain Free ... relief products is excited to release a line ... arthritis pain relief. These magnetic health bracelets for ... with gemstones. Customers often report pain relief in ... demonstration at shows. , "Having made magnetic bracelets ...

Breaking Medicine News(10 mins):Health News:Gluten-Free Products Market to Reach $6,206.2 Million by 2018 at a CAGR of 10.2% - New Report by MarketsandMarkets 2 Health News:Gluten-Free Products Market to Reach $6,206.2 Million by 2018 at a CAGR of 10.2% - New Report by MarketsandMarkets 3 Health News:Oswego Hospital Retains B. E. Smith to Recruit New COO 2 Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Offers improved hCG Diets With More Beneficial Nutritional Content, Possibly Offering Relief for Painful Symptoms of IBS 2 Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Offers improved hCG Diets With More Beneficial Nutritional Content, Possibly Offering Relief for Painful Symptoms of IBS 3 Health News:Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com 2 Health News:Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com 3 Health News:Handmade Magnetic Bracelets with Gemstones Announced by Pain Free Living 2

[0] Gluten-Free Products Market to Reach $6,206.2 Million by 2018 at a CAGR of 10.2% - New Report by MarketsandMarkets [0] Oswego Hospital Retains B. E. Smith to Recruit New COO [0] hCGTreatments / Diet Doc hCG Diets & Weight Loss Offers improved hCG Diets With More Beneficial Nutritional Content, Possibly Offering Relief for Painful Symptoms of IBS [0] Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com [0] Handmade Magnetic Bracelets with Gemstones Announced by Pain Free Living

... , OAKBROOK TERRACE, Ill., Sept. 21 ... 2009 recipients of the annual John M. Eisenberg Patient Safety and Quality ... feature a new international category. , , ... INDIVIDUAL ACHIEVEMENT , Gary S. ...

... , Awardees will work with industry ... , WASHINGTON, Sept. 21 The U.S. Food ... stimulate the development and availability of medical devices for children. ... , , A panel of six experts with ...

... , Research features from Mayo Clinic , ... the fall issue of Discovery,s Edge, Mayo Clinic,s research magazine. ... wish. Reprinting is allowed with proper attribution. Please include the following subscription ... Discovery,s Edge for subscription information. , ...

... , , MONTREAL, ... integrated absence & disability management, today announced the release ... to comply with complex and overlapping FMLA (Family and ... regulations. Presagia,s ADA Toolkit will supplement Presagia,s Leave ...

... Dalton ... adding Formulation Development to its list of integrated capabilities. , ... Toronto, Ontario (PRWEB) September 21, 2009 -- ... by adding Formulation Development to its list of integrated capabilities. , , ...

... , , ... of emergency department (ED) clinical documentation tools, today announced it ... recent recommendations of the Centers for Disease Control and Prevention ... the T-System Web site ( www.tsystem.com/h1n1flu ), now ...

Cached Medicine News:Health News:2009 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 2 Health News:2009 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 3 Health News:2009 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 4 Health News:FDA Awards Three Grants Designed to Stimulate Development of Pediatric Medical Devices 2 Health News:FDA Awards Three Grants Designed to Stimulate Development of Pediatric Medical Devices 3 Health News:Discovery's Edge Fall Issue -- http://discoverysedge.mayo.edu/ 2 Health News:Discovery's Edge Fall Issue -- http://discoverysedge.mayo.edu/ 3 Health News:Presagia Solution Helps Employers Navigate Overlapping ADA and FMLA Regulations 2 Health News:Presagia Solution Helps Employers Navigate Overlapping ADA and FMLA Regulations 3 Health News:Dalton Pharma Services Adds Formulation Development Services 2 Health News:T-System Updates Free Clinician H1N1 Templates to Latest CDC Guidelines, Adds Discharge Instructions 2 Health News:T-System Updates Free Clinician H1N1 Templates to Latest CDC Guidelines, Adds Discharge Instructions 3

2009 John M. Eisenberg Patient Safety and Quality Award Recipients Announced FDA Awards Three Grants Designed to Stimulate Development of Pediatric Medical Devices Discovery's Edge Fall Issue -- http://discoverysedge.mayo.edu/Presagia Solution Helps Employers Navigate Overlapping ADA and FMLA Regulations Dalton Pharma Services Adds Formulation Development Services T-System Updates Free Clinician H1N1 Templates to Latest CDC Guidelines, Adds Discharge Instructions

Duet Lumbar Allografts are comprised of a raised cancellous inner core providing biomechanical properties for rapid healing. Specially designed instruments facilitate the insertion of Duet Allografts...

Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....

Seletz-Gelpi Laminectomy Retractor, self-retaining with arms bent at right angles....

Scoville-Haverfield Hemilaminectomy Retractor...

Medicine Products:

Duet Lumbar Allograft System Graftech Posterior Ramp Seletz-Gelpi Laminectomy Retractor Scoville-Haverfield Hemilaminectomy Retractor